Tags

Type your tag names separated by a space and hit enter

Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
Horm Metab Res. 2003 Feb; 35(2):86-91.HM

Abstract

There is still some controversy concerning the effects of metformin in the treatment of Polycystic Ovary Syndrome (PCOS). The aim of this study was to asses the effect of metformin on clinical, metabolic and hormone parameters in obese women with PCOS. Thirty obese, non-diabetic women with PCOS received 500 mg of metformin or placebo, TID, over 90 days. Assessed parameters included body mass index, waist-to-hip ratio, blood pressure, FSH, LH, total testosterone, SHBG, fasting insulinemia, insulin-to-glucose ratio, total, HDL and LDL cholesterol, triglycerides, and menstrual cycles before and after the use of the drugs. Before treatment, patients did not differ in the two groups. After 90 days of metformin use, PCOS women presented significantly lower levels of total testosterone (p = 0.030) and total cholesterol (p = 0.023) compared to the women that used placebo. The other parameters did not differ between the groups. In conclusion, obese women with PCOS may benefit from the use of metformin through the reduction of hyperandrogenemia, total cholesterol, and possibly by restoration of regular menstrual cycles. Further studies with longer follow-ups are necessary to determine cardiovascular and endometrial metformin benefits and insulin-resistance decrease in women with polycystic ovary syndrome.

Authors+Show Affiliations

Gynecology and Obstetrics Service, Hospital of Santa Casa de Misericórdia de Porto Alegre, RS, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

12734787

Citation

Chou, K H., et al. "Clinical, Metabolic and Endocrine Parameters in Response to Metformin in Obese Women With Polycystic Ovary Syndrome: a Randomized, Double-blind and Placebo-controlled Trial." Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 35, no. 2, 2003, pp. 86-91.
Chou KH, von Eye Corleta H, Capp E, et al. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res. 2003;35(2):86-91.
Chou, K. H., von Eye Corleta, H., Capp, E., & Spritzer, P. M. (2003). Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 35(2), 86-91.
Chou KH, et al. Clinical, Metabolic and Endocrine Parameters in Response to Metformin in Obese Women With Polycystic Ovary Syndrome: a Randomized, Double-blind and Placebo-controlled Trial. Horm Metab Res. 2003;35(2):86-91. PubMed PMID: 12734787.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. AU - Chou,K H, AU - von Eye Corleta,H, AU - Capp,E, AU - Spritzer,P M, PY - 2003/5/8/pubmed PY - 2003/7/23/medline PY - 2003/5/8/entrez SP - 86 EP - 91 JF - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme JO - Horm Metab Res VL - 35 IS - 2 N2 - There is still some controversy concerning the effects of metformin in the treatment of Polycystic Ovary Syndrome (PCOS). The aim of this study was to asses the effect of metformin on clinical, metabolic and hormone parameters in obese women with PCOS. Thirty obese, non-diabetic women with PCOS received 500 mg of metformin or placebo, TID, over 90 days. Assessed parameters included body mass index, waist-to-hip ratio, blood pressure, FSH, LH, total testosterone, SHBG, fasting insulinemia, insulin-to-glucose ratio, total, HDL and LDL cholesterol, triglycerides, and menstrual cycles before and after the use of the drugs. Before treatment, patients did not differ in the two groups. After 90 days of metformin use, PCOS women presented significantly lower levels of total testosterone (p = 0.030) and total cholesterol (p = 0.023) compared to the women that used placebo. The other parameters did not differ between the groups. In conclusion, obese women with PCOS may benefit from the use of metformin through the reduction of hyperandrogenemia, total cholesterol, and possibly by restoration of regular menstrual cycles. Further studies with longer follow-ups are necessary to determine cardiovascular and endometrial metformin benefits and insulin-resistance decrease in women with polycystic ovary syndrome. SN - 0018-5043 UR - https://www.unboundmedicine.com/medline/citation/12734787/Clinical_metabolic_and_endocrine_parameters_in_response_to_metformin_in_obese_women_with_polycystic_ovary_syndrome:_a_randomized_double_blind_and_placebo_controlled_trial_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2003-39056 DB - PRIME DP - Unbound Medicine ER -